Fangzhou Jianke Partners with Volcano Engine to Enhance Innovative Patient-Centric Chronic Disease Management through Authoritative Health Education

“Treating diseases saves lives, and popularizing medical knowledge is also saving lives.”

Engaging, practical, and professional medical science communication services can serve as a bridge between doctors and patients, empowering individuals to actively participate in managing their own health. This facilitates a paradigm shift in medicine from “treating established diseases” to “preventing disease onset,” which is of significant importance for improving the health status of China’s population and represents a key approach to implementing the “Healthy China 2030” initiative.

Recently, Fangzhou Pharmaceutical Group, a chronic disease service platform, has launched an updated content platform in collaboration with Volcano Engine, a subsidiary of ByteDance. This partnership will inject richer and higher-quality health science popularization content into “Fangzhou Medical Chat,” Fangzhou Pharmaceutical Group’s interactive science communication platform. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical Group, stated that “Fangzhou Medical Chat,” which went live in November 2021, is designed to build an interactive, technology-driven professional medical education and science communication platform for doctors and patients through socialized and diversified service models.

Healthcare is a field characterized by high seriousness and strong academic rigor, which creates a certain sense of distance from the general public; yet, it remains an unavoidable topic for everyone. Therefore, as people increasingly prioritize their personal health and seek a clear understanding of their own health status, professional medical science communication has become essential.

Medical science popularization must be engaging and accessible to the public. This requires physicians to translate specialized medical terminology into language, text, images, or videos that are relatively easy to understand, enabling patients to immediately grasp the key messages conveyed. The professional foundation of medical science popularization also signifies that it is not a task for everyone; only participants who have established competitive barriers and advantages in specific fields can secure a foothold in this highly competitive industry.

A continuous supply of content serves as the raw material for conducting medical science popularization., and a stable pool of physicians forms the foundation for delivering continuous medical science popularization services. Fangzhou Pharmaceutical Group has established resource pathways through its in-house physician team, contracted industry experts, and self-built professional medical content production teams.

Meanwhile, Fangzhou Pharmaceutical Group is also actively laying out its presence in the physician-focused MCN (Multi-Channel Network) sector within the broader health industry, launching“Brand Doctor” Initiative, its new media center collaborates with thousands of physicians through live streaming, short videos, and popular science articles and images. It creates exclusive personal accounts for physicians, building a multidimensional professional image by facilitating interactive follow-up consultations, publishing specialized content, optimizing profile displays, and cultivating personal intellectual property (IP).

The authenticity and authority of content are key to medical science popularization.Medical science popularization must strike a balance between rigor and accessibility, without violating scientific principles. To this end, Fangzhou Pharmaceutical has empowered all content published on its platform with digital technology, enabling searches by department, disease type, topic, and content creator, while ensuring professional medical teams oversee review, verification, and final archival classification.

Medicine is a discipline in constant evolution, continually enriched by the passage of time and technological breakthroughs; platform information must keep pace with cutting-edge medical knowledge. In the current landscape, where the field of medical science popularization is highly competitive, how can one emerge as a “front-runner”? Fangzhou Pharmaceutical Group’s answer is clear: content is king.

Although the channels and habits through which the public accesses information have changed, the pursuit of high-quality content remains unwavering. “Content is king” means ensuring the authenticity of science popularization content while employing professional methods to synthesize information, thereby conveying deeper connotations and related extended content.

In this regard, Fangzhou Pharmaceutical Group leverages its years of advantage in internet-based chronic disease management services. By prioritizing high-quality content, it has established a comprehensive, end-to-end professional media service ecosystem in the field of health science popularization, while continuously deepening its efforts in supporting physicians’ creation of educational content. Furthermore, the Group has launched the “Brand Physician” initiative to provide targeted support for medical professionals in producing authoritative health education materials through articles, live streams, short videos, and other formats, thereby extending the reach of professional and credible health knowledge to a broader audience.

This collaboration with Volcengine also represents Fangzhou Pharmaceutical Group’s practical application of emerging technologies to promote “content integration.” Leveraging ByteDance’s vast content repository, Volcengine has amassed a rich reserve of health science popularization materials. By employing a human-AI parallel content curation model, it enables the rapid integration and secure deployment of articles, images, and short- and long-form videos onto the Fangzhou Pharmaceutical Group platform.

Precise Reach to Target Audiences Is the “Value Proposition” of Medical Science Popularization.When a piece of medical science popularization information precisely meets the needs of a specific user group, it demonstrates the true value of such education. Therefore, accurate delivery of information is crucial. Fangzhou Pharmaceutical Group leverages the user demographics and characteristics across its four major platforms—Internet Hospital, Chronic Disease Management Center, Online Pharmacy, and New Media Center—to enrich user interest profiles through content tagging. By dynamically adjusting and refining educational content based on the public’s actual needs, the group provides more targeted health education and services.

Take Fangzhou Pharmaceutical Group’s recently launched “Cartoon Health” column as an example. This column presents popular science content in the form of comic strips, transforming professional and authoritative health knowledge into engaging and practical information through the voices of two cartoon characters, “Dr. Fang” and “Dr. Zhou,” thereby enhancing user stickiness.

Fangzhou Pharmaceutical’s New Media Service Center has also established a top-tier matrix of health-focused media IPs characterized by rapid growth and comprehensive coverage, ensuring that professional health education content, such as illustrated articles, and other medical information provided by the platform are precisely delivered to end-users.

“Fangzhou Medical Chat” addresses the public’s pain points in accessing medical information by popularizing medical science, specifically alleviating the difficulties patients face during diagnosis and treatment due to a lack of professional, in-depth medical knowledge. From the perspective of Fangzhou Pharmaceutical’s overall strategic layout, “Fangzhou Medical Chat” disseminates professional and authoritative health knowledge, attracting more industry users and fostering a virtuous interactive cycle between users and doctors. This cycle is a crucial component of Fangzhou Pharmaceutical’s smart healthcare ecosystem.

First, “Fangzhou Medical Chat” closely engages with users, building an invisible interactive bridge for Fangzhou Pharmaceutical Group.“Fangzhou Medical Talk” centers on content to deliver professional and authoritative health knowledge, attracting and connecting patients with physicians while driving external traffic from platforms such as Douyin, Kuaishou, and WeChat Moments. It provides a communication scenario for information sharing and interaction between physicians and patients, as well as among physicians, thereby strengthening doctor-patient ties. For instance, it leverages an innovative “service + content” model to uncover patients’ demand for health services.

Secondly, we will consolidate more physician resources to provide talent support for online medical services such as Fangzhou Pharmaceutical Internet Hospital and the Chronic Disease Management Center.Through continuous interactive medical Q&A, a stable “acquaintance” doctor-patient relationship is established, fostering ongoing communication and facilitating the delivery of follow-up chronic disease management services. For instance, leveraging patient diagnosis and treatment data retained on the platform, physicians can formulate targeted care plans based on changes in the patient’s condition. This approach not only improves medication adherence but also enables a shift in chronic disease services from a treatment-oriented to a prevention-oriented model.

Finally, extend business operations to the backend and collaborate with Fangzhou Pharmaceutical’s Internet Hospital, Chronic Disease Management Center, online pharmacy, and innovative payment services to build a closed-loop internet healthcare ecosystem encompassing “medical care, patients, insurance, pharmaceuticals, and knowledge.”By facilitating orderly interactions within physician-only and physician-patient communities, Fangzhou Pharmaceutical helps doctors stay abreast of the most cutting-edge academic knowledge and provides patients with more comprehensive medication information and innovative chronic disease management solutions.

Meanwhile, Fangzhou Pharmaceutical leverages digital technologies such as the internet, big data, and AI to extend medical services from hospitals to homes through its online hospital and online pharmacy platforms. This enables at-home disease management for patients, thereby improving their healthcare experience, enhancing the timeliness of medical services, and increasing the accessibility of pharmaceutical services.According to data from Analysys, Fangzhou Pharmaceutical’s online pharmacy ranks first in monthly active users within the pharmaceutical distribution category, maintaining its leading position in the vertical sector.

In June 2022, nine departments, including the National Health Commission, the Publicity Department of the Central Committee of the Communist Party of China, and the Cyberspace Administration of China, jointly issued the “Guiding Opinions on Establishing and Improving Mechanisms for the Publication and Dissemination of Health Science Popularization Knowledge Across All Media,” which set forth standards and requirements for such mechanisms. These policy regulations guide industry development, enhancing the practical operability of medical science popularization.

For industry veterans like Fangzhou Pharmaceutical Group, thriving in a favorable market environment requires further clarifying their strategic positioning, staying true to their original mission in healthcare, and holding themselves to standards that exceed regulatory requirements, thereby ensuring sustainable and long-term growth.